Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Author:

Bringhen Sara1,Petrucci Maria Teresa2,Larocca Alessandra1,Conticello Concetta3,Rossi Davide4,Magarotto Valeria1,Musto Pellegrino5,Boccadifuoco Luana1,Offidani Massimo6,Omedé Paola1,Gentilini Fabiana2,Ciccone Giovannino7,Benevolo Giulia8,Genuardi Mariella1,Montefusco Vittorio9,Oliva Stefania1,Caravita Tommaso10,Tacchetti Paola11,Boccadoro Mario1,Sonneveld Pieter12,Palumbo Antonio1

Affiliation:

1. Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy;

2. Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy;

3. Divisione di Ematologia, Ospedale Ferrarotto, Azienda Policlinico-OVE, Catania, Italy;

4. Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale Amedeo Avogadro, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Italy;

5. Scientific Direction, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy;

6. Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy;

7. Unit of Clinical Epidemiology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica-Piemonte, Torino, Italy;

8. S.C. Ematologia, Dipartimento di Ematologia ed Oncologia, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, San Giovanni Battista, Torino, Italy;

9. Ematologia, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milano, Italy;

10. Ematologia, Ospedale S. Eugenio, Rome, Italy;

11. “Seràgnoli” Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; and

12. Erasmus University Medical Center Cancer Institute, Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands

Abstract

Key Points This is the first study of carfilzomib-cyclophosphamide-dexamethasone in elderly patients with newly diagnosed multiple myeloma. Carfilzomib-cyclophosphamide-dexamethasone induced high complete response rates and was associated with low toxicity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference29 articles.

1. Howlader N Noone AM Krapcho M SEER Cancer Statistics Review, 1975-2010. Available http://seer.cancer.gov/csr/1975_2010/. Accessed March 13, 2014

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.;Ferlay;Eur J Cancer,2013

3. Multiple myeloma.;Palumbo;N Engl J Med,2011

4. Continued improvement in survival in multiple myeloma and the impact of novel agents [abstract].;Kumar;Blood,2012

5. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.;San Miguel;N Engl J Med,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3